Alto Neuroscience
Tracked across 6 events · 37 articles · First seen Jul 25, 2025 · Last active May 29, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
Impact: Alto Neuroscience is facing a federal securities class action lawsuit due to allegedly misleading statements regarding the effectiveness of its drug ALTO-100 for MDD, which led to a significant drop in its stock price.
Jul 29, 2025 · 6 articles
Business
Impact: Alto Neuroscience is the target of a class action lawsuit alleging securities fraud due to misstatements about the effectiveness of its product pipeline, ALTO-100, and its financial prospects.
Aug 25, 2025 · 6 articles
Business
Impact: Alto Neuroscience is facing a class action lawsuit for allegedly making false and misleading statements regarding the effectiveness of its drug ALTO-100 for major depressive disorder, which could lead to significant financial and reputational damage.
Jul 25, 2025 · 7 articles
Tech
Impact: Alto Neuroscience is the journal where the new study was published.
Mar 18, 2026 · 6 articles
Tech
An international research team, co-led by the Istituto Italiano di Tecnologia>>> and the Child Mind Institute>>>, has identified two distinct subtypes of autism based on brain connectivity patterns: 'hyperconnectivity' and 'hypoconnectivity'. The study, coordinated by…
Impact: The journal Alto Neuroscience>>> published the research paper, disseminating the findings to the scientific community.
May 29, 2026 · 6 articles
80
Istituto Italiano di Tecnologia published paper Alto NeuroscienceAutism Subtypes Discovered...
80
Child Mind Institute published paper Alto NeuroscienceAutism Subtypes Discovered...
NEWSDESK
Track Alto Neuroscience live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard